No Cover Image

Journal article 510 views 53 downloads

Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial

Laith Alrubaiy Orcid Logo, Hayley Hutchings Orcid Logo, Andrea Louca, Frances Rapport Orcid Logo, Alan Watkins Orcid Logo, Shaji Sebastian, John Williams

Journal of Personalized Medicine, Volume: 12, Issue: 12, Start page: 2039

Swansea University Authors: Laith Alrubaiy Orcid Logo, Hayley Hutchings Orcid Logo, Frances Rapport Orcid Logo, Alan Watkins Orcid Logo, John Williams

  • jpm-12-02039.pdf

    PDF | Version of Record

    © 2022 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

    Download (481.59KB)

Check full text

DOI (Published version): 10.3390/jpm12122039

Abstract

Background: there is currently limited research examining the QoL of patients with Ulcerative colitis (UC) following treatment of acute severe colitis (ASUC). Objective: to examine the long-term QoL of ASUC patients enrolled in the CONSTRUCT trial following treatment of UC with infliximab or ciclosp...

Full description

Published in: Journal of Personalized Medicine
ISSN: 2075-4426
Published: MDPI AG 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa62152
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-12-09T11:27:45Z
last_indexed 2023-01-13T19:23:25Z
id cronfa62152
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-30T17:56:07.4647013</datestamp><bib-version>v2</bib-version><id>62152</id><entry>2022-12-09</entry><title>Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial</title><swanseaauthors><author><sid>62b59abd526b328bbb125dfaa9bdcd6d</sid><ORCID>0000-0002-6340-8244</ORCID><firstname>Laith</firstname><surname>Alrubaiy</surname><name>Laith Alrubaiy</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>bdf5d5f154d339dd92bb25884b7c3652</sid><ORCID>0000-0003-4155-1741</ORCID><firstname>Hayley</firstname><surname>Hutchings</surname><name>Hayley Hutchings</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>489cdf0e062781ca298433091b631488</sid><ORCID>0000-0002-4428-2826</ORCID><firstname>Frances</firstname><surname>Rapport</surname><name>Frances Rapport</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>81fc05c9333d9df41b041157437bcc2f</sid><ORCID>0000-0003-3804-1943</ORCID><firstname>Alan</firstname><surname>Watkins</surname><name>Alan Watkins</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>911a5c03419acf47eab0844e2cd5ab7f</sid><firstname>John</firstname><surname>Williams</surname><name>John Williams</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-12-09</date><deptcode>FGMHL</deptcode><abstract>Background: there is currently limited research examining the QoL of patients with Ulcerative colitis (UC) following treatment of acute severe colitis (ASUC). Objective: to examine the long-term QoL of ASUC patients enrolled in the CONSTRUCT trial following treatment of UC with infliximab or ciclosporin and to compare the differences in the QoL between the two drug treatments over time. Methods: The CONSTRUCT trial examined the cost and clinical effectiveness of infliximab and ciclosporin treatments for acute severe UC. We collected QoL questionnaire data from patients during the active trial period up to 36 months. Following trial completion, we contacted patients postannually for up to a maximum of 84 months. We collected QoL data using a disease-specific (CUCQ, or CUCQ+ for patients who had colectomy surgery) or generic (EQ5D-3L) questionnaire. We analysed QoL scores to determine if there was any difference over time and between treatments in generic or disease-specific QoL. Results: Following initial treatment with infliximab and ciclosporin, patients experienced a statistically significant improvement in both the generic and disease-specific QoL at three months. Generic scores remained fairly static for the whole follow-up period, reducing only slightly up to 84 months. Disease-specific scores showed a much sharper improvement up to 2 years with a gradual reduction in QoL up to 84 months. Generic and disease-specific QoL remained higher than baseline values. There was no significant difference between treatments in any of the QoL scores. Conclusions: Both infliximab and ciclosporin improve QoL following initial treatment for ASUC. QoL scores remain higher than at admission up to 84 months post-treatment.</abstract><type>Journal Article</type><journal>Journal of Personalized Medicine</journal><volume>12</volume><journalNumber>12</journalNumber><paginationStart>2039</paginationStart><paginationEnd/><publisher>MDPI AG</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2075-4426</issnElectronic><keywords>ulcerative colitis (UC); infliximab; ciclosporin; quality of life (QoL); EQ5D; CUCQ</keywords><publishedDay>9</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-12-09</publishedDate><doi>10.3390/jpm12122039</doi><url/><notes/><college>COLLEGE NANME</college><department>Medicine, Health and Life Science - Faculty</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>FGMHL</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>This study was funded (in part) by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, grant number 06/78/03.</funders><projectreference/><lastEdited>2022-12-30T17:56:07.4647013</lastEdited><Created>2022-12-09T11:22:59.4330080</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Laith</firstname><surname>Alrubaiy</surname><orcid>0000-0002-6340-8244</orcid><order>1</order></author><author><firstname>Hayley</firstname><surname>Hutchings</surname><orcid>0000-0003-4155-1741</orcid><order>2</order></author><author><firstname>Andrea</firstname><surname>Louca</surname><order>3</order></author><author><firstname>Frances</firstname><surname>Rapport</surname><orcid>0000-0002-4428-2826</orcid><order>4</order></author><author><firstname>Alan</firstname><surname>Watkins</surname><orcid>0000-0003-3804-1943</orcid><order>5</order></author><author><firstname>Shaji</firstname><surname>Sebastian</surname><order>6</order></author><author><firstname>John</firstname><surname>Williams</surname><order>7</order></author></authors><documents><document><filename>62152__26053__9d24b9e27cc54017892ea321a51eb76d.pdf</filename><originalFilename>jpm-12-02039.pdf</originalFilename><uploaded>2022-12-09T11:27:27.4817685</uploaded><type>Output</type><contentLength>493145</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2022 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-30T17:56:07.4647013 v2 62152 2022-12-09 Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial 62b59abd526b328bbb125dfaa9bdcd6d 0000-0002-6340-8244 Laith Alrubaiy Laith Alrubaiy true false bdf5d5f154d339dd92bb25884b7c3652 0000-0003-4155-1741 Hayley Hutchings Hayley Hutchings true false 489cdf0e062781ca298433091b631488 0000-0002-4428-2826 Frances Rapport Frances Rapport true false 81fc05c9333d9df41b041157437bcc2f 0000-0003-3804-1943 Alan Watkins Alan Watkins true false 911a5c03419acf47eab0844e2cd5ab7f John Williams John Williams true false 2022-12-09 FGMHL Background: there is currently limited research examining the QoL of patients with Ulcerative colitis (UC) following treatment of acute severe colitis (ASUC). Objective: to examine the long-term QoL of ASUC patients enrolled in the CONSTRUCT trial following treatment of UC with infliximab or ciclosporin and to compare the differences in the QoL between the two drug treatments over time. Methods: The CONSTRUCT trial examined the cost and clinical effectiveness of infliximab and ciclosporin treatments for acute severe UC. We collected QoL questionnaire data from patients during the active trial period up to 36 months. Following trial completion, we contacted patients postannually for up to a maximum of 84 months. We collected QoL data using a disease-specific (CUCQ, or CUCQ+ for patients who had colectomy surgery) or generic (EQ5D-3L) questionnaire. We analysed QoL scores to determine if there was any difference over time and between treatments in generic or disease-specific QoL. Results: Following initial treatment with infliximab and ciclosporin, patients experienced a statistically significant improvement in both the generic and disease-specific QoL at three months. Generic scores remained fairly static for the whole follow-up period, reducing only slightly up to 84 months. Disease-specific scores showed a much sharper improvement up to 2 years with a gradual reduction in QoL up to 84 months. Generic and disease-specific QoL remained higher than baseline values. There was no significant difference between treatments in any of the QoL scores. Conclusions: Both infliximab and ciclosporin improve QoL following initial treatment for ASUC. QoL scores remain higher than at admission up to 84 months post-treatment. Journal Article Journal of Personalized Medicine 12 12 2039 MDPI AG 2075-4426 ulcerative colitis (UC); infliximab; ciclosporin; quality of life (QoL); EQ5D; CUCQ 9 12 2022 2022-12-09 10.3390/jpm12122039 COLLEGE NANME Medicine, Health and Life Science - Faculty COLLEGE CODE FGMHL Swansea University Another institution paid the OA fee This study was funded (in part) by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, grant number 06/78/03. 2022-12-30T17:56:07.4647013 2022-12-09T11:22:59.4330080 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Laith Alrubaiy 0000-0002-6340-8244 1 Hayley Hutchings 0000-0003-4155-1741 2 Andrea Louca 3 Frances Rapport 0000-0002-4428-2826 4 Alan Watkins 0000-0003-3804-1943 5 Shaji Sebastian 6 John Williams 7 62152__26053__9d24b9e27cc54017892ea321a51eb76d.pdf jpm-12-02039.pdf 2022-12-09T11:27:27.4817685 Output 493145 application/pdf Version of Record true © 2022 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license true eng https://creativecommons.org/licenses/by/4.0/
title Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
spellingShingle Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
Laith Alrubaiy
Hayley Hutchings
Frances Rapport
Alan Watkins
John Williams
title_short Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_full Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_fullStr Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_full_unstemmed Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
title_sort Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
author_id_str_mv 62b59abd526b328bbb125dfaa9bdcd6d
bdf5d5f154d339dd92bb25884b7c3652
489cdf0e062781ca298433091b631488
81fc05c9333d9df41b041157437bcc2f
911a5c03419acf47eab0844e2cd5ab7f
author_id_fullname_str_mv 62b59abd526b328bbb125dfaa9bdcd6d_***_Laith Alrubaiy
bdf5d5f154d339dd92bb25884b7c3652_***_Hayley Hutchings
489cdf0e062781ca298433091b631488_***_Frances Rapport
81fc05c9333d9df41b041157437bcc2f_***_Alan Watkins
911a5c03419acf47eab0844e2cd5ab7f_***_John Williams
author Laith Alrubaiy
Hayley Hutchings
Frances Rapport
Alan Watkins
John Williams
author2 Laith Alrubaiy
Hayley Hutchings
Andrea Louca
Frances Rapport
Alan Watkins
Shaji Sebastian
John Williams
format Journal article
container_title Journal of Personalized Medicine
container_volume 12
container_issue 12
container_start_page 2039
publishDate 2022
institution Swansea University
issn 2075-4426
doi_str_mv 10.3390/jpm12122039
publisher MDPI AG
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Background: there is currently limited research examining the QoL of patients with Ulcerative colitis (UC) following treatment of acute severe colitis (ASUC). Objective: to examine the long-term QoL of ASUC patients enrolled in the CONSTRUCT trial following treatment of UC with infliximab or ciclosporin and to compare the differences in the QoL between the two drug treatments over time. Methods: The CONSTRUCT trial examined the cost and clinical effectiveness of infliximab and ciclosporin treatments for acute severe UC. We collected QoL questionnaire data from patients during the active trial period up to 36 months. Following trial completion, we contacted patients postannually for up to a maximum of 84 months. We collected QoL data using a disease-specific (CUCQ, or CUCQ+ for patients who had colectomy surgery) or generic (EQ5D-3L) questionnaire. We analysed QoL scores to determine if there was any difference over time and between treatments in generic or disease-specific QoL. Results: Following initial treatment with infliximab and ciclosporin, patients experienced a statistically significant improvement in both the generic and disease-specific QoL at three months. Generic scores remained fairly static for the whole follow-up period, reducing only slightly up to 84 months. Disease-specific scores showed a much sharper improvement up to 2 years with a gradual reduction in QoL up to 84 months. Generic and disease-specific QoL remained higher than baseline values. There was no significant difference between treatments in any of the QoL scores. Conclusions: Both infliximab and ciclosporin improve QoL following initial treatment for ASUC. QoL scores remain higher than at admission up to 84 months post-treatment.
published_date 2022-12-09T04:21:33Z
_version_ 1763754422958030848
score 11.013148

Similar Items